Non erectile dysfunction application of sildenafil

Herz

Volumn 28, Issue 4, 2003, Pages 325-333

  Cremers, Bodo ^a   Böhm, Michael ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Cardioprotection; Endothelial dysfunction; Female sexual dysfunction; Gastroenterology; Heart failure; Infertility; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Viagra

Indexed keywords

ILOPROST; SILDENAFIL;

ADJUVANT THERAPY; CARDIOPULMONARY INSUFFICIENCY; DYNAMIC EXERCISE; ENDOMETRIUM; ERECTILE DYSFUNCTION; FEMALE INFERTILITY; FEMALE SEXUAL DYSFUNCTION; GASTROINTESTINAL DISEASE; HEART PROTECTION; HUMAN; LOW DRUG DOSE; OBSERVATION; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; REVIEW; UTERUS BLOOD FLOW;

EID: 0037592333     PISSN: 03409937     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00059-003-2473-0     Document Type: Review

References (47)

1. Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol 1999;83:3C-12C.
2. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52.
3. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
4. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
5. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342:1866-70.
6. Ahn HS, Foster M, Cable M, Pitts BJ, Sybertz EJ. Ca/CaM-stimulated and cGMP-specific phosphodiesterases in vascular and nonvascular tissues. Adv Exp Med Biol 1991;308:191-7.
7. Bogdan M, Humbert M, Francoual J, Claise C, Duroux P, Simonneau G, Lindenbaum A. Urinary cGMP concentrations in severe primary pulmonary hypertension. Thorax 1998;53:1059-62.
8. Wilkens H, Guth A, König J, Forestier N, Cremers B, Hennen B, Böhm M, Sybrecht GW. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001;104:1218-22.
9. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissman N, Seeger W, Grimminger F. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-22.
10. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, Gunther A, Walmrath D, Seeger W, Grimminger F. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:855-900.
11. Zhao L, Mason NA, Morrell NW, Kojonazarov B, Sadykov A, Maripov A, Mirrakhimov MM, Aldashev A, Wilkins MR. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001;104:424-8.
12. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16:1568-9.
13. Jackson G, Chambers J. Sildenafil for primary pulmonary hypertension: short- and long-term symptomatic benefit. Int J Clin Pract 2002;55:397-8.
14. Laumann E, Paik A, Rosen R. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999;281:537-44.
15. Goldstein I, Berman JR. Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes. Int J Impot Res 1998;10:584-90.
16. Mooradian AD, Greiff V. Sexuality in older women. Arch Intern Med 1990;150:1033-8.
17. Berman JR, Berman LA, Lin H, Flaherty E, Lahey N, Goldstein I, Cantey-Kiser J. Effect of sildenafil on subjective and physiological parameters of the female sexual response in women with sexual arousal disorder. J Sex Marital Ther 2001;27:411-20.
18. D'Amati G, di Gioia CR, Bologna M, Giordano D, Giorgi M, Dolci S, Jannini EA. Type 5 phosphodiesterase expression in the human vagina. Urology 2002;60:191-5.
19. Sarrell PM. Ovarian hormones and vaginal blood flow using laser Doppler velocimetry to measure effects in a clinical trial of postmenopausal women. Int J Impot Res 1998;10:591-3.
20. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998;338:1397-404.
21. Berman LA, Berman JR, Bruck D, Pawar RV, Goldstein I. Pharmacotherapy or psychotherapy? Effective treatment for FSD related to unresolved childhood sexual abuse. J Sex Marital Ther 2001;27:421-5.
22. Sher G, Fisch JD. Vaginal sildenafil (Viagra): a preliminary report of a novel method to improve uterine artery blood flow and endometrial development in patients undergoing IVF. Hum Reprod 2000;15:806-9.
23. Sher G, Fisch JD. Effect of vaginal sildenafil on the outcome of in vitro fertilization (IVF) after multiple IVF failures attributed to poor endometrial development. Fertil Steril 2002;78: 1073-6.
24. Mearin M, Guarner F, Salas A, Riveros-Moreno V, Moncada S, Malagelada JR. Patients with achalasia lack nitric oxide synthase in the gastro-oesophagealjunction. Eur J Clin Invest 1993;23:724-8.
25. Bortolotti M, Mari C, Lopilato C, Porrazzo G, Miglioli M. Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. Gastroenterology 2000;118:253-7.
26. Cassella RR, Brown AI, Sayre L, Ellis FH. Achalasia of the esophagus: pathologic and etiologic considerations. Ann Surg 1964; 160:474-86.
27. Desai KM, Sessa WC, Vane JR. Involvement of nitric oxide in the reflex relaxation of the stomach to accommodate food or fluid. Nature 1991;351:477-9.
28. Russo A, Fraser R, Adachi K, Horowitz M, Boeckxstaens G. Evidence that nitric oxide mechanisms regulate small intestinal motility in humans. Gut 1999;44:72-6.
29. Bortolotti M, Mari C, Lopilato C, La Rovere L, Miglioli M. Sildenafil inhibits gastroduodenal motility. Aliment Pharmacol Ther 2001;15:157-61.
30. Abrahamsson H. Gastrointestinal motility disorders in patients with diabetes mellitus. J Intern Med 1995;237:403-9.
31. Koch KL. Diabetic gastropathy: gastric neuromuscular dysfunction in diabetes mellitus: a review of symptoms, pathophysiology, and treatment. Dig Dis Sci 1999;44:1061-75.
32. Tomita R, Tanjoh K, Fujisaki S, Fukuzawa M. The role of nitric oxide (NO) in the human pyloric sphincter. Gastroenterology 1999;46:2999-3003.
33. Vanderwinden JM, Mailleux P, Schiffmann SN, Vanderhaeghen JJ, De Laet MH. Nitric oxide synthase activity in infantile hypertrophic pyloric stenosis. N Engl J Med 1992;327:511-5.
34. Takahashi T, Nakamura K, Itoh H, Sima AA, Owyang C. Impaired expression of nitric oxide synthase in the gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 1997;113:1535-44.
35. Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, Snyder SH, Ferris CD. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000;106:373-84.
36. Valenza V, Bianco A, D'Errico G, Grieco A, D'Andrea G, Alfei B. Has sildenafil a role in acute diabetic gastroparesis? Two cases evaluated with radionuclide study. Eur J Nucl Med 2001;28:P5639.
37. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med 1990;323:27-36.
38. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36:845-51.
39. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA. Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes. Diabetes Care 2002;25:1336-9.
40. Halcox JP, Nour KR, Zalos G, Mincemoyer RA, Waclawiw M, Rivera CE, Willie G, Ellahham S, Quyyumi AA. The effect of sildenafil on human vascular function, platelet activation, and myocardial ischemia. J Am Coll Cardiol 2002;40:1232-40.
41. Jaarsma T, Dracup K, Walden J, Stevenson LW. Sexual function in patients with advanced heart failure. Heart Lung 1996;25:262-70.
42. Bocchi EA, Guimaraes G, Mocelin A, Bacal F, Bellotti G, Ramires JF. Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction. Circulation 2002;106: 1097-103.
43. Bocchi EA, Vilella de Moraes AV, Esteves-Filho A, Bacal F, Auler JO, Carmona MJ, Bellotti G, Ramires AF. L-arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol 2000;23:205-10.
44. Kloner RA, Zusman RM. Cardiovascular effects of sildenafil citrate and recommendations for its use. Am J Cardiol 1999;84:11-7.
45. Ockaili R, Salloum F, Hawkins J, Kukreja RC. Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 2002;283:H1263-9.
46. Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. Arthritis Rheum 2001;44:1841-7.
47. Lichtenstein JR. Use of sildenafil citrate in Raynaud's phenomenon: comment on the article by Thompson et al. Arthritis Rheum 2003;48:282-3.